Trials Offered by a Specific Doctor

HERBERT IRVING COMPREHENSIVE CANCER CENTER
Investigator
Suzanne Lentzsch, MD
Phone
(646) 317-4840
Email
sl3440@cumc.columbia.edu

Dr. Lentzsch is an Associate Professor of Clinical Medicine and the Director of the Multiple Myeloma and Amyloidosis Program at the College of Physicians and Surgeons of Columbia University and at New York Presbyterian Hospital in New York. She is at New York Presbyterian Hospital/ Columbia University Medical Center. After receiving her degrees from the Humboldt University/ Charité Berlin, Germany, she completed her residency and fellowship at Humboldt University. She did a research fellowship, studying the mechanism of action of thalidomide and its derivatives in multiple myeloma, in the Jerome Lipper Multiple Myeloma Center under the mentorship of Dr Kenneth Anderson at the Dana-Farber Cancer Institute, Boston, MA, USA.

Dr. Lentzsch was recruited in August 2004 to the University of Pittsburgh and University of Pittsburgh Cancer Institute (UPCI), PA, USA, and served as Clinical Director of the Multiple Myeloma Program at UPCI before accepting the position as Director of the Multiple Myeloma and Amyloidosis Program at Columbia University Medical Center. She cares primarily for patients with plasma cell dyscrasia including MGUS, Multiple Myeloma, Amyloidosis, POEMS and Waldenstrom's Macroglobulinemia.

Dr. Lentzsch is an internationally recognized expert in the field of Multiple Myeloma and Amyloidosis. She serves as a SWOG Myeloma Committee Member, SWOG Study Coordinator and International Myeloma Foundation "Black Swan Research Initiative" committee member. She is a member of the standing advisory board for the evaluation of Secondary Primary Malignancies associated with IMiDs.


Clinical Studies Managed By Dr. Lentzsch:
More InfoTitleSponsorIRB Number
Details[CLOSED] Study For Previously Treated Patients Of Multiple Myeloma Therapy Using Carfilozmib, Pomalidomide, and DexamethasoneAcademic Myeloma Consortium AMyCAAAJ2354
Details[CLOSED] Study For Previously Treated Patients Of Amyloidosis Using Bendamustine and DexamethasoneCephalon Inc.AAAJ7800
Details[CLOSED] Study For Patients Of Multiple Myeloma Therapy Prior To Stem Cell Transplant With Or Without Lenalidomide/DexamethasoneCelgene Inc.AAAJ2355
Details[CLOSED] Study For Previously Treated Patients Of Light-Chain Amyloidosis Using Study Drug CarfilzomibAcademic Myeloma Consortium AMyCAAAL4653
Details[CLOSED] Study For Previously Treated Patients Of Light-Chain Amyloidosis Using study drugs Dexamethasone and MLN9708Millenium Pharmaceuticals Inc.AAAM1254
Details[CLOSED] Study for newly diagnosed patients of multiple myeloma with study drug (Carfilzomib)Onyx Therapeutics Inc.AAAJ2359
Details[CLOSED] A study for subjects with relapsed or refractory multiple myeloma using study drugs daratumumab, bortezomib and dexamethasoneJanssen Research & Development, LLCAAAO1956
Details[CLOSED] A study for patients with newly diagnosed multiple myeloma using study drugs lenalidomide, bortezomib and DexamethasonDana Farber Cancer InstituteAAAN7006
Details[CLOSED] A study for patients with Multiple Myeloma using study drug SelinexorKaryopharm Therapeutics, IncAAAP1309
Details[CLOSED] A study for patients with AL amyloidosis using study drug NEOD001Prothena TherapeuticsAAAP5356
DetailsA study for patients with relapsed of refractory multiple myeloma using study drug KPT-330Karyopharm Therapeutics, IncAAAQ6904
DetailsStudy to Measure the Impact of MMprofiler on Treatment Intention in Multiple Myeloma Patients (PROMMIS)SkylineDx, Inc.AAAR4254
DetailsStudy of Drug in Subjects with Multiple MyelomaAmgenAAAR5312
DetailsFirst in Human (FIH) Study of REGN5458 in Patients With Relapsed or Refractory Multiple MyelomaRegeneron Pharmaceuticals, IncAAAS2588
DetailsAssessing Financial Difficulty in Patients with Blood Cancers (Chronic Lymphocytic Leukemia and/or Multiple Myeloma)NIHAAAS5789